Figure 2.

PFS according to NF‐κB mutation status. Kaplan‐Meier analysis of PFS in the DNAseq‐evaluable population (A) according to presence (mut) or absence (WT) of mutations in the non‐canonical NF‐κB pathway, and (B) with IRd and placebo‐Rd according to mutation status. CI, confidence interval; HR, hazard ratio; IRd, ixazomib‐lenalidomide‐dexamethasone; mut, NF‐κB pathway mutation; NF‐κB, nuclear factor kappa B; NR, not reached; PFS, progression‐free survival; Rd, placebo‐lenalidomide‐dexamethasone; WT, wild‐type NF‐κB pathway